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ABSTRACT 
Objective: It is to develop a simple, valid and rapid chromatographic method for quantification of saxagliptin in rat’s serum in order to study 
saxagliptin pharmacokinetic parameters in sucralose fed rats simultaneously to detect any interaction possibility between saxagliptin and sucralose 
in rats.  
Methods: In our developed method of analysis, mobile phase consisted of phosphate buffer (pH =4) and methanol (70:30) v/v at flow rate of 1 
ml/min with UV detection at 230 nm., C8 column of separation was used with temperature of 40 C ° using injection volume of 50 µl, samples run 
time was 10 min, and sildenafil citrate was used as internal standard. saxagliptin was given to rats orally of (2g/kg) dose while sucralose was given 
with (11 mg/kg/day) dose.  
Results: A successful HPLC method was validated and developed to determine saxagliptin in rats serum, overall intra-day precision and accuracy 
were reasonable with coefficient of variation percentage CV % values range (o.14-4.03) and accuracy % range (99.5-104), while inter-day precision 
and accuracy showed accepted precision with CV% range (0.15-2.81) and accuracy % range (99.9-116). The coefficient of correlation was 0.99949 
with reasonable sensitivity and selectivity. Combination effect of saxagliptin with sucralose on saxagliptin serum profile was demonstrated as 
strong statistical effect according to Cohen’s d and significant P values too.  
Conclusion: A successful HPLC method was validated and developed to quantify saxagliptin in rats serum, combination effect of saxagliptin with 
sucralose over all time intervals of saxagliptin serum profile was demonstrated as strong statistical effect.  
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The article has a wrong part of introduction by mistake of authors. 
On request to remove the wrong part of this article and which by 
mistake we put another introduction for another drug place in place 
will be read as for another drug, of the published article. Reason is 
that a big mistake because we talk about Saxagliptin in the article 
but the introduction is about Pioglitazone.  
This part must be removed urgently (in manuscript) 
Saxagliptin: ((±)-5-(4-(2-(5-ethyl-2-pyridinyl) ethoxy) phenyl) 
methyl)-2, 4-) thiazolidinedione monohydrochloride [1], the 
structural formula is as shown in fig. 1. It belongs to a different 
chemical class with different pharmacological action than the 
sulfonylureas, metformin, or the α-glucosidase inhibitors [2], it is a 
compound that belongs to a group named “thiazolidinediones” 
family, an oral antidiabetic agent that acts by decreasing insulin 
resistance [3]. Saxagliptin has the same mechanism of action by 
which all thiazolidinediones act inside the body.  
Its mechanism of action made it as one of the most effective drugs 
that is used in the management of type 2 diabetes mellitus [4, 5], 
saxagliptin can improve the sensitivity to insulin in muscle and 
adipose tissue [2, 7] which helps in hepatic gluconeogenesis 
inhibition [8] and improves glycemic control by reducing circulating 
insulin levels [9, 10]. Type 2 diabetes patients are usually treated 
with numerous pharmacological compounds which increases the 
susceptibility to be exposed to risky drug-drug interactions [7]. 
Saxagliptin was marketed at USA in 1999, nowadays; it is marketed 
in more than 40 countries worldwide [6]. 
And the following part must substitutes (in the place of removed one) 
Saxagliptin HCL is one of a new generation of orally hypo-glycemic 
(anti-diabetic medication) from the dipeptidyl peptidase-4 inhibitor 
class of type 2 drugs for the treatment of diabetic (1-5). Saxagliptin 
one of a huge class of diabetes mellitus drugs known as dipeptidyl 
peptidase-4 (DPP-4) inhibitors. This DPP-4 is an enzyme that 
breaks down incretin hormones. As a DPP-4 inhibitor (3-6), 
Saxagliptin slows down the breakdown of incretin hormones, 
increasing the level of these hormones in the body. It is this 
increase in incretin hormones that is responsible for the beneficial 
actions of X-gliptins, including increasing insulin level production 
in answering to meals and decreasing the amount of glucose that 
the liver organ produces.  
Because incretin hormones are more active in response to higher 
blood glucose/sugar levels, the risk of dangerously low blood 
sugar (hypoglycaemia) is low with Saxagliptin. Saxagliptin is 
available as tablets at the dose of 5 and 10 mg in the market under 
the brand name of Onglyza®, by and Astra-Zeneca in Jordan 
Market. Chemically (1S, 3S, 5S)-2-[(2S)-Amino (3-hydroxytricyclo 
[3.3.1. 13, 7] dec-1-yl) acetyl]-2-azabicyclo [3.1.0] hexane-3-carbo-
nitrile mono-hydrochloride with empirical formula is C18H25N3O2. 
HCl (1-10). 
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